Takeda Pharmaceutical Co. Ltd. is building out its Nycomed unit's infrastructure in Russia in preparation for expected changes to Russia's reimbursement system that would transform the country's market from one focused on branded generics to one more able to pay for innovator drugs.

Takeda acquired Nycomed last year for €9.6 billion ($13.6 billion) net of cash and debt (see BioCentury, May 23, 2011).